Company Profile
Axsome Stock Price, News & Analysis
- Ticker:
- AXSM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
238.37 USD (-1.09%)
Close
Last updated: July 27, 2026
11.4B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, AXSM closed down 1.09% at $238.37. No new same-company headline was identified in the current news window.
Company overview
Business overview
Axsome Therapeutics is a neuroscience company focused on central nervous system disorders such as depression, migraine, and sleep-related conditions. Its business combines commercial products with a pipeline aimed at major CNS markets.
Geographic Base and Sector Classification
Axsome is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a strong neuroscience focus.
Business Model Characteristics
The company depends on product launches, label expansion, and clinical development across CNS programs. Investors watch revenue growth, market access, and whether the pipeline can keep widening the commercial base.
Position Within the Biotechnology Landscape
Axsome occupies one of the strongest growth stories in neuroscience biotech. It has more commercial grounding than a typical development-stage name, but still reacts to CNS pipeline milestones.
Future catalysts
Axsome’s catalysts are Auvelity growth, Sunosi execution, and any CNS-label expansion that extends the franchise. The stock tends to respond quickly when the commercial base keeps widening.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Axsome (AXSM)?
Axsome (AXSM) most recently closed at 238.37 USD, a -1.09% move versus the previous session.
What is the market cap of Axsome (AXSM)?
Axsome currently has a market capitalization of 11.4B USD on BioPharmSignal.
What does Axsome do?
Axsome Therapeutics is a neuroscience company focused on central nervous system disorders such as depression, migraine, and sleep-related conditions. Its business combines commercial products with a pipeline aimed at major CNS markets.
On which exchange is AXSM stock listed?
Axsome (AXSM) is associated with NASDAQ, United States, Biopharma.
What is Axsome?
Axsome’s catalysts are Auvelity growth, Sunosi execution, and any CNS-label expansion that extends the franchise.
Which conditions is Axsome targeting with Axsome?
Axsome is associated with neuroscience based on its company overview and current catalyst commentary.
How does Axsome describe recent progress with Axsome?
Axsome’s catalysts are Auvelity growth, Sunosi execution, and any CNS-label expansion that extends the franchise.
What is Therapeutics?
Axsome Therapeutics is a neuroscience company focused on central nervous system disorders such as depression, migraine, and sleep-related conditions.